#USA #New York #Neurology #American Parkinson Disease Association #Walter Koroshetz

Dr. Walter Koroshetz Joins APDA's Scientific Advisory Board

The American Parkinson Disease Association (APDA) has made a significant appointment by welcoming Dr. Walter Koroshetz to its Scientific Advisory Board (SAB). Dr. Koroshetz is a distinguished neurologist and neuroscientist who has made numerous contributions to the field of neurological research, particularly in the realm of Parkinson's Disease (PD).

Having previously served as the Director of the National Institute of Neurological Disorders and Stroke (NINDS), Dr. Koroshetz brings a wealth of experience and insight to his new role. His leadership in various pioneering programs, including the Accelerated Medicine Partnership in Parkinson's Disease, has provided a robust foundation for advancing research and care related to this complex illness.

A Commitment to Parkinson's Research

Dr. Koroshetz’s dedication to PD research is commendable. Throughout his career, he has been a vigorous advocate for innovative research approaches that target the underlying mechanisms of Parkinson's disease. His expertise will be invaluable in refining the APDA’s research funding strategy, focusing on supporting groundbreaking science that has the potential to transform the lives of those living with PD.

Dr. Rebecca Gilbert, Chief Mission Officer at APDA, expressed enthusiasm about having Dr. Koroshetz join the SAB, highlighting his longstanding commitment to the patients affected by neurological disorders. “We are honored that he is choosing to continue serving the Parkinson's community and we are excited about the insights he will bring to our processes,” she remarked.

The APDA's Scientific Advisory Board includes a diverse group of highly esteemed scientists who are committed to carefully assessing and recommending innovative research proposals aimed at combating Parkinson's disease. With the addition of Dr. Koroshetz, the board now boasts 16 members, each bringing their unique expertise to the table.

Advancing Research Accessibility

One of the key goals of the APDA, guided by its SAB, is to empower early-stage investigators in the field. This includes not only researchers who are newcomers to the field of Parkinson's research but also those at the start of their scientific careers. By selecting the most promising projects with high-impact potential for funding, the APDA aims to stimulate innovation and advance our understanding of Parkinson’s disease.

In addition to its standard grant funding, the SAB has recently launched a special bridge funding initiative. This effort addresses the unexpected financial challenges faced by existing APDA-supported researchers, ensuring that critical projects can continue without interruption—a vital support mechanism in today’s ever-changing research landscape.

A Vision for the Future

Dr. Koroshetz’s trajectory has encompassed significant leadership roles and initiatives not just at NINDS, but also at Massachusetts General Hospital and Harvard Medical School. His return to the Parkinson’s research community through APDA signifies an ongoing commitment to collaborative efforts aimed at unveiling new and effective therapies.

As the APDA continues to pursue its mission of improving the lives of individuals living with Parkinson’s disease, the addition of Dr. Koroshetz to the Scientific Advisory Board helps ensure that its research efforts will remain at the forefront of innovation. The APDA aims for not just incremental improvements in care but a future where Parkinson's disease can be comprehensively understood and, ideally, cured.

For those who wish to learn more about APDA’s research initiatives or how they can support the organization, they are encouraged to visit www.apdaparkinson.org or to reach out directly via phone or email.

Dr. Walter Koroshetz’s joining APDA symbolizes a beacon of hope for many who are impacted by Parkinson's disease, paving the way for transformative advancements in the field.